文献

重组抗小鼠GITR单克隆抗体(克隆号DTA-1) ，大鼠IgG2b Lambda（Recombinant Anti-mouse GITR Monoclonal Antibody (Clone: DTA-1), Rat IgG2b Lambda，货号：PA007502.r2b Syd Labs）

大鼠抗小鼠GITR单克隆抗体DTA-1（大鼠IgG2b lambda）可与小鼠GITR蛋白（糖皮质激素诱导的TNFR相关蛋白或肿瘤坏死因子受体超家族18，TNFRSF 18）发生反应。DTA-1单克隆抗体可与主要由CD4+CD25+调节性T细胞（Treg）以及CD25+ CD4+ CD8-胸腺细胞表达的小鼠GITR反应。

我们的重组DTA-1抗体包含大鼠抗小鼠GITR单克隆抗体（杂交瘤克隆名称或编号：DTA-1）的部分（可变区）或完整氨基酸序列。

抗小鼠GITR单抗(DTA-1)流式部分参考文献:

1. A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
Bu, M. T., et al. Monoclon Antib Immunodiagn Immunother. 2022 Aug;41(4):202-209. PMID: 35925787
“Unconjugated and fluorophore-conjugated PD-1 mAbs (1A12, rat IgG2a; RMP1-14, rat IgG2a; and RMP1-30, rat IgG2b) and PD-L1 mAbs (10F.9G2, rat IgG2b; MIH6, rat IgG2a) were purchased from…Owing to the widespread use of both PD-1 mAbs 1A12 and RMP1-14 in experimental mouse models, we compared the avidities of these two mAbs. …The 1A12 antimouse PD-1 mAb bound to mPD-1–transfected Jurkat cells in a dose-dependent manner with an apparent affinity of 0.42 nM, while RMP1-14 antibody bound with a much weaker apparent affinity of 28.8 nM. …This result was also seen with 1A12 and RMP1-14 mAbs from a different vendor (Fig. S1). …In case the lower avidity of RMP-1-14 (anti-mouse CD279 antibody) was a consequence of transfection, we assayed the antibody binding to exhausted murine CD8 T cells naturally expressing PD-1…”

2. Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies
Metzger, P., et al. Sci Rep. 2018 Jun 11;8(1):8810. PMID: 29892077
“We assessed PD-1 expression by flow cytometry and compared the two mainly used antibody clones (29 F.1A12 and RMP1-14 antibodies), which were also included in the above-mentioned study. …We observed PD-1 staining exclusively in the dead cell fraction for both clones 29 F.1A12 and RMP1-14 mAb, respectively…”

3. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
Grasselly, C., et al. Front Immunol. 2018 Oct 9;9:2100. PMID: 30356816
“Anti-PD1 antibody(clone RMP1-14) or anti-PDL1 (clone 10F.9G2) mAb (12,5 mg/kg, ip, q1wk) were administered in combination with (A,C) methotrexate (1 mg/kg, ip, q1wk), vinblastine (0.1 mg/kg, ip, q1wk), doxorubicin(1 mg/kg, ip, q1wk) and cisplatin(1 mg/kg,ip, q1wk, MVAC) in SC bladder cancer MB49 and MBT-2, and with (B) cyclophosphamide (CTX, 100 mg/kg, ip, q1wk) and doxorubicin (DOX, 2 mg/kg, ip, q1wk) in SC metastatic breast cancer 4T1, and with (D) capecitabine (CAPE, 250 mg/kg, po 5 days a week) and oxaliplatin (OXA, 5 mg/kg, ip, q1wk) in SC colorectal cancer MC38. …Effect of anti-PD1 antibody (clone RMP1-14) or anti-PDL1 (clone 10F.9G2) antibody, 12,5 mg/kg, i.p., q1wk, in combination with cyclophosphamide (CTX) 100 mg/kg, i.p, q1wk and doxorubicin (DOX) 2 mg/kg, i.p, q1wk in SC metastatic breast cancer 4T1 (A), methotrexate 1mg/kg, i.p, q1wk and vinblastine 0,1 mg/kg, i.p, q1wk and doxorubicin 1 mg/kg, i.p, q1wk and cisplatin 1 mg/kg i.p, q1wk (MVAC) in SC bladder cancer MB49 (B), Data are shown as Mean + SEM, n = 5 to 6 (A), n = 6 (B).”

4. Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma
DeAzevedo, R., et al. J Immunother Cancer. 2024 Oct 30;12(10):e009690. PMID: 39477243
“On days 7, 11, 15, and 19, mice received 250 ug anti-PD-1 antibody RMP1-14 i.p. or isotype control antibody. …On days 7, 11, 15, and 19, mice received 250 ug anti-PD-1 mAb RMP1-14 i.p. or isotype control antibody. …In this system, mice were treated when measurable tumors emerged with 10 doses of c-Met inhibitor and 5 doses of the PD-1 antibody RMP1-14. …On days 2, 4, 6, 8, and 10 post-palpation, mice received 250 ug anti-PD-1 RMP1-14 antibody i.p. or isotype control antibody. …On days 2, 4, 6, 8, and 10 post-palpation, mice received 250 ug anti-PD-1 RMP1-14 mAb i.p. or isotype control antibody.”

5. Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy
Denis, M., et al. Front Immunol. 2023 Jan 10;13:1011943. PMID: 36703964
“When the tumor volume reached 150 mm3, mice were randomized and received first treatment of anti-PD-1 antibody (RMP1-14, 12.5 mg/kg per week, intraperitoneal (IP)). …The mice are randomized based on their weight and receive 48 hours after the operation their first anti-PD-1 treatments (RMP1-14, 12.5 mg/kg per week, IP)…”